US 9127053
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
granted A61KA61K2039/505A61K39/39558
Quick answer
US patent 9127053 (Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof) held by CytomX Therapeutics, Inc. expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CytomX Therapeutics, Inc.
- Grant date
- Tue Sep 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 33
- CPC classes
- A61K, A61K2039/505, A61K39/39558, A61K47/68031, A61K47/6811